Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Cure8 research brief
Why This Matters
People with UC and their clinicians often consider infection risks when choosing biologic therapy. This study examines whether vedolizumab and anti‑TNF drugs differ in risk for C. difficile infection, a relevant complication in IBD care.
Who Should Pay Attention
Clinicians treating ulcerative colitis, gastroenterology researchers, and adult patients considering or receiving vedolizumab or anti‑TNF therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study looked back at patient records to compare C. difficile infections in people with UC starting vedolizumab versus anti-TNF drugs. The raw incidence rates and adjusted hazard ratios did not show a statistically significant difference between the drug groups.
The analysis used marginal structural Cox models and included sensitivity analyses restricted to biologic‑naïve patients; results were consistent but imprecise. The authors note wide confidence intervals, meaning the study may be underpowered to detect a real difference.
If you take VDZ or an anti‑TNF, this paper does not provide clear evidence that one drug raises or lowers CDI risk compared with the other; larger prospective studies are needed to be sure.
Keep In Mind
This is a retrospective cohort with modest sample size and relatively few events; authors report wide confidence intervals and recommend validation in larger prospective cohorts. The abstract-format source limits detail on case definitions, concomitant medications, or CDI testing protocols.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
AuthorsJiahui Huang, Ziying Jiang, Jun Deng +6 more
InstitutionDepartment of Clinical Laboratory, the Sixth Affiliated Hospital, Sun Yat-sen University, NO.26 Er Heng Road, Yuancun Street, Tianhe District, Guangzhou, 510655, China; Biomedical Innovation Center, the Sixth Affiliated Hospital, Sun Yat-sen University, NO.26 Er Heng Road, Yuancun Street, Guangzhou, Tianhe District, 510655, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 19, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest We have no conflicts of interest to declare for all authors.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The association between the MCM6 LCT-13910C>T variant and bone mineral density in patients with inflammatory bowel disease.
People with IBD face higher osteoporosis risk; this study looked for a genetic variant (LCT-13910C>T) that might affect bone density but found no clear link in this cohort, so it does not change current bone-health...
Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
Synergistic Effect of VSL#3TM and Vedolizumab for Ulcerative colitis: Preliminary Evidence from a Real-world Single-Arm study
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....